MedTrace Logo

Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

NCT07226453 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-07

No results posted yet for this study

Summary

This is a multi-site study of the pharmacodynamic effects and efficacy of metformin in children and young adults with recurrent or progressive Posterior Fossa Group A (PFA) ependymoma.

Conditions

  • Posterior Fossa Ependymal Tumor

Interventions

DRUG

Metformin

Given orally (PO)

PROCEDURE

Planned Surgical Resection

Undergo planned surgery as part of regular care

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo MRI imaging

PROCEDURE

Specimen Collection

Tumor Tissue, blood, and cerebral spinal fluid (CSF) may be collected for correlative analysis.

PROCEDURE

MR spectroscopy (MRS)

Undergo MRS imaging

Sponsors & Collaborators

Principal Investigators

  • Sabine Mueller, MD, PhD · University of California, San Francisco

  • Santhosh A Upadhyaya, MD · University of Michigan, C. S. Mott Children's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
1 Year
Max Age
39 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-05
Primary Completion
2028-04-30
Completion
2030-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07226453 on ClinicalTrials.gov